Advanced Cancer, Endometrial Cancer, Metastatic Cancer, Oncology, Recurrent Cancer
Conditions
Brief summary
This is a national observational retrospective multi-site chart review study of patients with advanced, recurrent or metastatic endometrial carcinoma.
Interventions
DRUGChemotherapy
Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
Sponsors
ARCAGY/ GINECO GROUP
Merck Sharp & Dohme LLC
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. Adult women ≥ 18 years at index date. 2. Documented diagnosis of advanced recurrent or metastatic endometrial cancer not eligible to primary complete surgery. Patients with interval surgery after primary CT may be eligible. 3. Index date should represent at least the first\* or second line\*\* chemotherapy systemic treatment and occur between, 1, January 2019 and 31, December 2019. 4. do not express refusal to her personal data processing or did not express her refusal for deceased patients.
Exclusion criteria
1. No clinical records for tumor imaging or administration of anti-cancer therapy. 2. Patients with active malignancy other than EC cancer which contribute significantly to the clinical impairment of the patient during the study period, according to investigator opinion. 3. Patients lost to follow-up, defined as patients whose last follow-up information occurs less than two years after index date (unless the patient is deceased). 4. Patient did not receive chemotherapy systemic treatment. 5. Patient undergo treatment by pembrolizumab or another immunotherapy in first line (cohort 1) or second line (cohort 2) during the eligibity (inclusion) period.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical, biological and treatment characteristics | up to 3 years | Description of the data |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progession Free Survival real world (rwPFS) | through study completion, an average of 1 year | From the date of initiation of the treatment in the corresponding line to the date of progression or death |
| Overall Survival (OS) | through study completion, an average of 1 year | From the date of initiation of the treatment in the corresponding line to the date of death |
Countries
France
Outcome results
None listed